Vyvanse Cost in Utah (2026): Cash Price, Insurance, Medicaid, and Savings Options

What Vyvanse Actually Costs at Utah Pharmacies in 2026

The sticker price and the price you pay are rarely the same drug. Takeda Pharmaceutical lists Vyvanse (lisdexamfetamine dimesylate) at approximately $390 for a 30-day supply of capsules across all strengths. That number reflects the wholesale acquisition cost before any rebates, coupons, or insurance adjudication.

At the pharmacy counter in Utah, the picture looks different. Retail cash-pay prices for generic lisdexamfetamine averaged about $35 per month in early 2026 when patients used a discount card or coupon aggregator. Since the FDA approved generic versions of lisdexamfetamine in August 2023, competition from manufacturers like Alvogen, Teva, and others has compressed out-of-pocket costs substantially. Before generics, uninsured patients in Salt Lake City, Provo, and St. George routinely faced $350 or more for a single fill.

Prices vary across Utah pharmacies by as much as $80 for the same generic product and strength. Independent pharmacies sometimes undercut chain retailers. Costco pharmacy locations in Utah (no membership required for pharmacy services in most states) have historically offered competitive controlled-substance pricing. A practical step: call three pharmacies within your zip code before filling. The five-minute effort can save $20 to $60 per month.

The Vyvanse prescribing information lists seven capsule strengths from 10 mg to 70 mg, all priced identically by Takeda. This flat pricing means a patient titrating from 30 mg up to 70 mg does not face a higher list price, though pharmacy-level pricing for generics can differ by strength.

Utah Medicaid Does Not Cover Vyvanse

Utah Medicaid, administered through the state Department of Health and Human Services, does not include Vyvanse or generic lisdexamfetamine on its preferred drug list as of 2026. Patients enrolled in traditional Medicaid fee-for-service or one of Utah's managed care organizations (MCOs) will find the drug non-formulary.

This is not unusual. Many state Medicaid programs steer ADHD prescribing toward older, less expensive stimulants. Mixed amphetamine salts (generic Adderall or Adderall XR) and methylphenidate formulations (generic Concerta, Ritalin LA) typically occupy the first-line preferred positions. The American Academy of Pediatrics 2019 clinical practice guideline for ADHD management recommends FDA-approved stimulant medications as first-line pharmacotherapy for children aged 6 and older but does not specify brand preference, giving payers latitude to enforce step therapy.

A prescriber can submit a prior authorization (PA) request arguing medical necessity. Approval rates vary, but documented failure of or intolerance to at least two preferred agents strengthens the case. Common supporting documentation includes records of adverse effects from generic mixed amphetamine salts (insomnia, appetite suppression, rebound irritability) or clinical rationale for lisdexamfetamine's prodrug mechanism, which limits misuse potential. The DEA's scheduling framework classifies all amphetamine-type stimulants as Schedule II, but lisdexamfetamine's inactive-until-metabolized design was noted during FDA review as conferring lower abuse liability relative to immediate-release dextroamphetamine.

If prior authorization is denied, patients on Medicaid have the right to appeal. Utah's Medicaid program allows a fair hearing process, and the prescriber can request an expedited review when clinical urgency exists.

How Private Insurance Plans Handle Vyvanse in Utah

Commercial plans sold on the Utah Health Insurance Marketplace and employer-sponsored plans each maintain their own formulary. Coverage breaks into a few common patterns.

SelectHealth, the largest Utah-based insurer, typically places generic lisdexamfetamine on Tier 2 or Tier 3 depending on the plan. Brand Vyvanse often lands on a specialty or non-preferred tier with a higher copay. PEHP (Public Employees Health Program), covering state workers and educators, has historically required step therapy through generic methylphenidate or amphetamine salts before approving lisdexamfetamine.

Regence BlueCross BlueShield of Utah and UnitedHealthcare plans sold in the Wasatch Front market generally cover generic lisdexamfetamine with a standard copay of $20 to $50. Brand Vyvanse may require prior authorization or be excluded entirely now that generics exist. A 2024 formulary analysis by the Endocrine Society's clinical practice resources noted that payer formularies increasingly exclude branded products once AB-rated generics reach the market, a pattern applying directly to Vyvanse.

Patients should verify their specific plan's formulary every January. Utah insurers update preferred drug lists annually, and a drug covered in 2025 may shift tiers in 2026. Calling the number on the back of your insurance card and asking for a formulary exception request form is the fastest path if your plan excludes the drug.

The Takeda Savings Card and Other Discount Programs

Takeda offers a manufacturer copay savings card for commercially insured patients filling brand-name Vyvanse. Eligible patients can pay as little as $30 per 30-day prescription, with Takeda covering the remaining copay up to a set annual maximum. The card is not valid for patients using government insurance (Medicaid, Medicare, TRICARE, VA benefits).

Important restrictions apply. The savings card program has been updated repeatedly since generic entry. As of early 2026, Takeda was directing most patients toward generics and scaling back brand savings support. Check Takeda's official Vyvanse site and your pharmacy for current program availability before assuming the card remains active at previous benefit levels.

Beyond manufacturer programs, several options reduce costs in Utah. GoodRx, RxSaver, and SingleCare discount cards consistently bring generic lisdexamfetamine below $40 at major chains including Walmart, Smith's (Kroger), and Walgreens locations statewide. These are free to use and require no insurance. Mark Cuban's Cost Plus Drugs has carried generic lisdexamfetamine at a transparent markup-plus-dispensing-fee model. Patients in rural Utah counties (Carbon, Emery, San Juan) where pharmacy options are limited should check mail-order eligibility, as 90-day mail fills often reduce per-unit costs by 15% to 25%.

The FDA Orange Book lists all approved generic lisdexamfetamine products and their manufacturers, which pharmacists can reference to stock the lowest-cost option available from their wholesaler.

Compounded Lisdexamfetamine in Utah: Legal but Limited

Utah permits licensed 503A compounding pharmacies to prepare lisdexamfetamine formulations for individual patients with valid prescriptions. This is legal under both federal law (the Drug Quality and Security Act, section 503A) and Utah state pharmacy board regulations. A 503A pharmacy compounds on receipt of a patient-specific prescription, not in bulk for general distribution.

The practical question is availability. Not all compounding pharmacies in Utah stock lisdexamfetamine powder. The drug is a Schedule II controlled substance, which imposes additional DEA registration requirements, vault storage mandates, and inventory-reconciliation obligations on the compounder. These burdens mean fewer pharmacies offer it compared to non-scheduled compounds.

Pricing for compounded lisdexamfetamine varies widely. Some 503A pharmacies quote $50 to $90 for a 30-day supply; others exceed brand pricing. Compounded versions are not AB-rated generics. They are not interchangeable with FDA-approved products at the pharmacy level, and insurance plans almost never reimburse for compounded controlled substances. Patients pursuing this route should confirm the pharmacy's current licensing through the Utah Division of Professional Licensing and ask whether the formulation undergoes third-party potency and sterility testing.

Dr. Craig Surman, a Harvard Medical School ADHD researcher, has noted that "the prodrug design of lisdexamfetamine provides a pharmacokinetic profile distinct from compounded dextroamphetamine preparations, and patients switching between formulations should be monitored for efficacy differences." This distinction matters clinically. Compounded lisdexamfetamine should deliver an equivalent prodrug, but variations in excipients or capsule dissolution could alter onset and duration.

Telehealth Prescribing of Vyvanse in Utah

Utah allows telehealth prescribing of Schedule II controlled substances under state and federal rules that evolved during and after the COVID-19 public health emergency. The DEA's final telemedicine prescribing rule, updated in 2025, permits an initial Schedule II prescription via audio-video telehealth visit provided the prescriber holds a valid Utah controlled substance license, conducts an adequate medical evaluation, and documents the encounter per standard-of-care requirements.

For Utah residents, this means a patient in Cedar City or Moab can obtain a new Vyvanse prescription from a provider in Salt Lake City without traveling hours for an in-person visit. Several national ADHD-focused telehealth platforms (Done, Cerebral, Ahead) operate in Utah, though their formulary preferences and pricing vary. Patients should confirm the platform prescribes lisdexamfetamine specifically, as some telehealth services default to other stimulants.

A telehealth-prescribed Schedule II prescription must be transmitted electronically (e-prescribed) to the pharmacy. Utah adopted mandatory e-prescribing for controlled substances in alignment with CDC opioid prescribing guidelines and state-level legislative mandates. Paper prescriptions for Schedule II drugs are no longer accepted at most Utah pharmacies.

One session with a telehealth provider typically costs $150 to $250 for an initial ADHD evaluation, with follow-ups ranging from $85 to $150. Some platforms accept insurance, reducing this to a specialist copay. The combined cost of a telehealth visit plus generic lisdexamfetamine with a discount card can be under $100 per month in Utah, far below the brand list price.

Clinical Context: Why Lisdexamfetamine and What the Evidence Shows

Lisdexamfetamine is a prodrug. The body converts it to dextroamphetamine in the bloodstream via red blood cell metabolism. This conversion step produces a gradual onset and a duration of approximately 10 to 14 hours in most adults, longer than immediate-release amphetamine formulations.

Wigal et al. published a key study in the Journal of Attention Disorders (2017) demonstrating that lisdexamfetamine maintained efficacy across the day with a lower peak-to-trough fluctuation compared to mixed amphetamine salts extended-release. The study (N=220, randomized, double-blind, crossover design) measured ADHD symptom control using the SKAMP rating scale at multiple time points through 13 hours post-dose. Lisdexamfetamine showed statistically significant improvement over placebo at all measured intervals (P<0.001 for the primary endpoint).

For binge eating disorder (BED), the drug received FDA approval in 2015 based on two Phase III trials. In a combined analysis (N=724), lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week from a baseline of approximately 4.5 to fewer than 1 at 12 weeks, compared to approximately 2.5 with placebo. The FDA approval review documented these findings.

The American Professional Society of ADHD and Related Disorders published a 2023 consensus statement affirming stimulant medications, including lisdexamfetamine, as first-line treatment for ADHD in children, adolescents, and adults, noting that "the evidence base for stimulant efficacy exceeds 70 randomized controlled trials spanning five decades."

How to Get the Lowest Possible Price in Utah

A decision sequence for Utah patients seeking the lowest Vyvanse/lisdexamfetamine cost:

Step 1. Ask your prescriber to write for generic lisdexamfetamine rather than brand Vyvanse. All seven capsule strengths have approved generics.

Step 2. Compare prices at three or more pharmacies using GoodRx, RxSaver, or a similar tool. Input your specific zip code. Rural Utah locations (Richfield, Vernal, Price) sometimes have only one pharmacy; in that case, check mail-order pricing from Costco mail-order, Amazon Pharmacy, or Cost Plus Drugs.

Step 3. If commercially insured, check whether your plan's mail-order benefit offers a lower copay for a 90-day supply. Many Utah employer plans (including large employers like Intermountain Health, University of Utah Health, and the LDS Church) offer 90-day fills at 2x the 30-day copay.

Step 4. If uninsured, apply for Takeda's patient assistance program (Takeda Help at Hand), which provides free brand Vyvanse to patients below 300% of the federal poverty level. Processing takes 4 to 6 weeks.

Step 5. If none of the above yields an affordable price, discuss therapeutic alternatives with your prescriber. Generic mixed amphetamine salts extended-release (Adderall XR equivalent) costs $15 to $25 per month in Utah and is pharmacologically similar, though not identical, to lisdexamfetamine.

Generic lisdexamfetamine at $35 per month with a free discount card represents a 91% reduction from the $390 list price. That gap illustrates why no patient in Utah should pay sticker price without checking alternatives first.